Trabeculectomy

Trabeculectomy
Intervention
ICD-9-CM 12.64
MeSH D014130

Trabeculectomy is a surgical procedure used in the treatment of glaucoma to relieve intraocular pressure by removing part of the eye's trabecular meshwork and adjacent structures. It is the most common glaucoma surgery performed and allows drainage of aqueous humor from within the eye to underneath the conjunctiva where it is absorbed. This outpatient procedure was most commonly performed under monitored anesthesia care using a retrobulbar block or peribulbar block or a combination of topical and subtenon (Tenon's capsule) anesthesia. Due to the higher risks associated with bulbar blocks, topical analgesia with mild sedation is becoming more common. Rarely general anesthesia will be used, in patients with an inability to cooperate during surgery.

Procedure

An initial pocket is created under the conjunctiva and Tenon's capsule and the wound bed is treated for several seconds to minutes with mitomycin C (MMC, 0.5–0.2 mg/ml) or 5-fluorouracil (5-FU, 50 mg/ml) soaked sponges. These chemotherapeutics help to prevent failure of the filter bleb from scarring by inhibiting fibroblast proliferation. Alternatively, non-chemotherapeutic adjuvants can be implemented to prevent super scarring by wound modulation, such as the ologen collagen matrix implant.[1][2][3][4][5] Some surgeons prefer "fornix-based" conjunctival incisions while others use "limbus-based" construction at the corneoscleral junction which may allow easier access in eyes with deep sulci. A partial thickness flap with its base at the corneoscleral junction is then made in the sclera after careful cauterization of the flap area, and a window opening is created under the flap with a Kelly-punch to remove a portion of the sclera, Schlemm's canal and the trabecular meshwork to enter the anterior chamber. Because of the fluid egress the iris will partially prolapse through the sclerostomy and is usually therefore grasped to perform an excision called iridectomy. This iridectomy will prevent future blockage of the sclerostomy. The scleral flap is then sutured loosely back in place with several sutures. The conjunctiva is closed in a watertight fashion at the end of the procedure.

Mechanism

Intraocular pressure may be lowered by allowing drainage of aqueous humor from within the eye to the following routes: (1) filtration through the sclerostomy around the margins of the scleral flap into the filtering bleb that forms underneath the conjunctiva, (2) filtration through outlet channels in the scleral flap to underneath the conjunctiva, (3) filtration through connective tissue of the scleral flap to underneath the conjunctiva. into cut ends of Schlemm's canal, (4) aqueous flow into cut ends of Schlemm's canal into collector channels and episcleral veins and (5) into a cyclodialysis cleft between the ciliary body and the sclera if tissue is dissected posterior to the scleral spur.

Postoperative care

Glaucoma medications are usually discontinued to improve aqueous humor flow to the bleb. Topical medications consist typically of antibiotic drops four times per day and anti-inflammatory therapy e.g. with prednisolone drops every two hours. A shield is applied to cover the eye until anesthesia has worn off (that also anesthetizes the optic nerve) and vision resumes.

Patients are instructed to call immediately for pain that cannot be controlled with over the counter pain medication or if vision decreases, to not rub the eye and to wear the shield at night for several days after surgery.

If 5-FU was used during surgery or if no anti-fibrotic agent was applied, 5 mg 5-FU daily can be injected in the 7–14 postoperative days. In the following days to weeks sutures that hold the scleral flap down can be cut by laser suture lysis to titrate the intraocular pressure down by improving outflow. In laser suture lysis a red light laser and a contact lens are used to penetrate noninvasively the overlying conjunctiva and cut the black nylon suture. Some surgeons prefer adjustable flap sutures during the trabeculectomy that can be loosened later on with forceps in a slit lamp office procedure.

Postoperative challenges

Conclusion

Trabeculectomy is the most common invasive glaucoma surgery. It is highly effective in the treatment of advanced glaucoma as demonstrated in major glaucoma studies. Even if a prior trabeculectomy has failed a second trabeculectomy can be performed at a different site. If scarring is the main reason, anti-fibrotic and anti-inflammatory therapy has to be intensified in the second procedure. Alternatively, insertion of a glaucoma valve device can be used.

Modifications of trabeculectomy

Trabeculectomy has undergone numerous modifications, e.g. filtering trepanotrabeculectomy (TTE) is a modification of the operation after J. Fronimopoulos. A triangular scleral flap is created which is approximately one-half as thick as the sclera. Trepanation is performed with a 2 mm trephine. The scleral edge of the trepanation opening is heat-cauterized.[8]

Additional deep scleral dissection can also be performed in the scleral bed with trabeculectomy, first introduced by T. Dada et al.;[9] deep scleral excision is performed in non-penetrating filtering surgeries but not traditionally in trabeculectomy. The space created from the deep scleral dissection is proposed to accommodate certain biocompatible spacer or devices in order to prevent subscleral fibrosis and to maintain good filtering results in this modified operation.

Various adjunctive devices have been used with trabeculectomy, to maintain drainage of aqueous humor and to maintain the patency of bleb. There is low-quality evidence that usage of Ex-PRESS implant, a miniature stainless steel shunt, and human amniotic membrane as adjuncts with trabeculectomy have been associated with reduced intraocular pressure in patients after a one-year follow-up, compared to standard trabeculectomy.[10]

Research

A Cochrane review sought to compare the effectiveness of fornix-based versus limbal-based conjunctival flaps for patients undergoing trabeculectomy.[11] There were no statistically significant differences between the two procedures in regards to surgery failure rate, mean intraocular pressure at follow-up, and postoperative complications.[11]

Currently, there are no published trials which compare the efficacy and safety of ab interno trabeculectomy with Trabectome with other procedures for treating glaucoma.[12]

See also

References

  1. ↑ Cillino, S; Pace F Di; Cillino G; Casuccio A (Sep 2011). "Biodegradable collagen matrix implant vs mitomycin-C as an adjuvant in trabeculectomy: a 24-month, randomized clinical trial". Eye. 25 (12): 1598–606. doi:10.1038/eye.2011.219. PMC 3234465Freely accessible. PMID 21921953.
  2. ↑ Marey, H M; S S Mandour; A F Ellakwa (Oct 2012). "Subscleral Trabeculectomy with Mitomycin-C Versus Ologen for Treatment of Glaucoma". Journal of Ocular Pharmacology and Therapeutics. 29 (3): 330–4. doi:10.1089/jop.2012.0120. PMID 23113645.
  3. ↑ Papaconstantinou, Dimitris; Georgalas I; Karmiris E; Diagourtas A; Koutsandrea C; Ladas I; Apostolopoulos M; Georgopoulos G (Feb 2010). "Trabeculectomy with ologen versus trabeculectomy for the treatment of glaucoma: a pilot study". Acta Ophthalmol. 88 (1): 80–85. doi:10.1111/j.1755-3768.2009.01753.x. PMID 19900209.
  4. ↑ Rosentreter, Andre; Schild AM; Jordan JF; Krieglstein GK; Dietlein TS (Sep 2010). "A prospective randomised trial of trabeculectomy using mitomycin C vs an ologen implant in open angle glaucoma". Eye. 24 (9): 1449–57. doi:10.1038/eye.2010.106. PMID 20733558.
  5. ↑ Nilforushan, Naveed; Yadgari M; Falavarjani KG; Afshar AE (2010). "Evaluation of subconjunctival Oculusgen* implantation as an adjunct to trabeculectomy". Iranian J Ophthalmol. 22 (2): 55–62. Retrieved 3 November 2011.
  6. ↑ Dietlein TS, Rosentreter A. "Secondary subconjunctival implantation of biodegradable porous collagen matrix for treating ocular hypotony following trabeculectomy with mitomycin C" (PDF). 2012 EGS Congress, Copenhagen. Retrieved Dec 2012. Check date values in: |access-date= (help)
  7. ↑ Kouros P, Loesche CC, Sbeity Z, Palmiero PM. "Ologen implants as an adjuvant for revision surgery after failed trabeculectomy" (PDF). 2012 EGS Congress, Copenhagen. Retrieved Dec 2012. Check date values in: |access-date= (help)
  8. ↑ Sjarov N, Draganska A (July 1984). "[Filtering trepano-trabeculectomy with sponge-like scar]". Klin Monbl Augenheilkd (in German). 185 (1): 55–8. doi:10.1055/s-2008-1054571. PMID 6482288.
  9. ↑ Tanuj, D; Amit S; Saptorshi M; Meenakshi G (May 2013). "Combined Subconjunctival and Subscleral Ologen Implant Insertion In Trabeculectomy". Eye. E-pub ahead of print; doi:10.1038/eye.2013.76 (7): 889. doi:10.1038/eye.2013.76. PMC 3709396Freely accessible. PMID 23640614.
  10. ↑ Wang X, Khan R, Coleman A (2015). "Device-modified trabeculectomy for glaucoma". Cochrane Database Syst Rev. 12: CD010472. doi:10.1002/14651858.CD010472.pub2. PMID 26625212.
  11. 1 2 Al-Haddad C, Abdulaal M, Al-Moujahed A, Ervin AM (2015). "Fornix-based versus limbal-based conjunctival trabeculectomy flaps for glaucoma". Cochrane Database Syst Rev. 11: CD009380. doi:10.1002/14651858.CD009380.pub2. PMID 26599668.
  12. ↑ Hu K, Gazzard G, Bunce C, Wormald R (2016). "Ab interno trabecular bypass surgery with Trabectome for open angle glaucoma". Cochrane Database Syst Rev. 8: CD011693. doi:10.1002/14651858.CD011693.pub2. PMID 27526051.
This article is issued from Wikipedia - version of the 12/3/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.